West Branch Capital’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-28
Closed -$617 – 418
2025
Q3
$617 Hold
28
– – ﹤0.01% 396
2025
Q2
$617 Hold
28
– – ﹤0.01% 410
2025
Q1
$589 Hold
28
– – ﹤0.01% 434
2024
Q4
$668 Hold
28
– – ﹤0.01% 417
2024
Q3
$727 Hold
28
– – ﹤0.01% 399
2024
Q2
$667 Hold
28
– – ﹤0.01% 399
2024
Q1
$816 Hold
28
– – ﹤0.01% 390
2023
Q4
$931 Hold
28
– – ﹤0.01% 409
2023
Q3
$791 Hold
28
– – ﹤0.01% 403
2023
Q2
$968 Hold
28
– – ﹤0.01% 404
2023
Q1
$854 Hold
28
– – ﹤0.01% 412
2022
Q4
$801 Hold
28
– – ﹤0.01% 410
2022
Q3
$1K Hold
28
– – ﹤0.01% 416
2022
Q2
$1K Hold
28
– – ﹤0.01% 395
2022
Q1
$1K Hold
28
– – ﹤0.01% 397
2021
Q4
$2K Hold
28
– – ﹤0.01% 413
2021
Q3
$2K Hold
28
– – ﹤0.01% 386
2021
Q2
$3K Buy
+28
New +$2.38K ﹤0.01% 394

Other funds holding ARKG

West Branch Capital's ARKG Position: Q4 2025 in Review

West Branch Capital sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 28 shares — an estimated $617 sold.

West Branch Capital first reported a position in ARKG in Q2 2021 and held it in 18 quarters. The position peaked at $3K in Q2 2021. 241 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

  • West Branch Capital reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
  • West Branch Capital sold 28 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $617.
  • West Branch Capital first reported a position in ARK Genomic Revolution ETF in Q2 2021 and held it in 18 quarters.
  • West Branch Capital's ARK Genomic Revolution ETF position peaked at $3K in Q2 2021.
  • 241 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on West Branch Capital's 13F filing for Q4 2025, filed 16 Jan 2026.